Letters sent to healthcare professionals in May 2018

Letters were sent about azithromycin, Lynparza鈻�(Olaparib), Xgeva鈻� (denosumab), Lymphoseek (tilmanocept), ReoPro (abciximab) and dolutegravir; you still have time to complete a quick survey to tell us your views on the way medicines safety issues are communicated.

From:
Medicines and Healthcare products Regulatory Agency
Published
22 June 2018
Therapeutic area:
Cancer, Cardiovascular disease and lipidology, Haematology and oncology, Immunosuppression and transplantation, Infectious disease, Obstetrics, gynaecology and fertility and Radiology and imaging

In May 2018, letters were sent to healthcare professionals about:

  • Azithromycin:

  • 尝测苍辫补谤锄补鈻�(翱濒补辫补谤颈产):

  • Xgeva鈻� (denosumab):

  • Lymphoseek (tilmanocept) radiopharmaceutical preparation:

  • ReoPro (abciximab) 2 mg/mL solution for injection or infusion:

  • Tivicay鈻� (dolutegravir), Triumeq鈻� (dolutegravir, abacavir, lamivudine), Juluca鈻� (dolutegravir, rilpivirine):

You still have time to complete this to tell us your views on the way medicines safety issues are communicated and how we might improve this to better support safe and effective use.

Article citation: Drug Safety Update volume 11, issue 11; June 2018: 4.

Updates to this page

Published 22 June 2018

Related content